PSIP1 and systemic lupus erythematosus: Although the treatment strategies (Supplemental Table 1) and disease duration of our LN and NLN-SLE patients were different, which was almost inevitable in clinical settings, a similar prevalence of anti-DFS70 antibodies in our newly onset LN and NLN-SLE patients was also be observed.